Concord Biotech Limited
NSE CONCORDBIO.NS
Concord Biotech Limited EBIT Margin for the year ending March 31, 2024: 41.31%
-
Concord Biotech Limited EBIT Margin for the year ending March 31, 2023 was 38.58%, a 10.54% change year over year.
-
Concord Biotech Limited EBIT Margin for the year ending March 31, 2022 was 34.91%, a -32.90% change year over year.
-
Concord Biotech Limited EBIT Margin for the year ending March 31, 2021 was 52.02%, a 37.37% change year over year.
-
Concord Biotech Limited EBIT Margin for the year ending March 31, 2020 was 37.87%.
| Date | EBIT Margin | EPS (Basic) | EPS (Diluted) | Shares (Basic, Weighted) |
|---|
Don’t Miss A Beat
| CEO | Mr. Ankur Vaid |
| IPO Date | Aug. 18, 2023 |
| Location | India |
| Headquarters | 16th Floor, B-Wing |
| Employees | 1,377 |
| Sector | Health Care |
| Industries | |
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email